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THE PRACTIC'AL ROLEofimmunotherapy
in cancer management is largely based
tipon the theory that ttimour cells possess
surface antigens that are i-ecognized by
the host as foreign targets for inimuno-
logical destrtiction. Oncofoetal Antigen I
(OFA-1), first desci-ibed by Irie et al.
(1976), is a membrane antigen on various
histological types of human cancer cells
that cross-reacts with human foetal braiii
tissue, but has iiot been fotiiid in foetial
liver, spleen, thymus and small intestine,
or on any iiormal adult, biopsy cells.
OFA-1 has been detected in 52% of
melanomas, 39% of sarcomas, 43% of
breast tumours and 22% of gastrointes-
tinal tumours (Irie et al., 1976) and has
been shown to be immunogenic in man
by its ability to provoke humoral anti-
body in patients witli cancer as detected
by immunofluoreseence (Trie et al., 1979a)
and immune-adherence teehniqties (Irie
et al., -1979b). Thus OFA-1 can be dis-
tinguished from. CEA and a-foetoprotein,
two well defined foetal antigens, by its
distribution in human foetal tissues,
immunogenic properties and antigenic
specificity oii tumour cells. Although anti-
bodies to OFA-1 are found in about 60%
of sera from melanoma patients, the
clinical significance of anti-OFA-1 is
presently unknown. We recently reported
that postoperative Stage 11 melanoma
patients whose anti-OFA-1 titres were
consistently liigh did iiot have disease,
i-ectii-i-ence, whereas those patients whose
aiitibodv titres were initially low btit in-
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creased more than 4-fol(I did liave recur-
rence of their disease (Trie et al., 1978).
In order to define the role ofanti-OFA-1
in relation to in vivo tumour growth, we
tested the cvtotoxic capability of this
antibodyagain'st, variotis OFA-I+ cultured
tumotir-cell lines. These iiieluded two
melanoma cell lines, UCLA-SO-M14 (M1.4)
and UCLA-80-MIO (MIO), a sarcoma cell
line, UCLA-SO-SI (SI) and a breast-
carcinoma cell line, MDA-MB-436 (436).
Serum samples were obtained from 14
nielanoma patients displaying high levels
of antri-OFA-1 antibodY by immune ad-
herence and membrane immunofluores-
cence, as defined in our previous work
(Irie et al., 1976, 1979a). This population
included 10 patients receiving immuno-
therapywithtumour-cellvaccineandBCG,
3 receiving BCG alone and one patient
JJ'Tho had surgical excision but no adjuvant
therapy. All sera were decomple-
mented by heat treatment at 56T for
30 min and stored at 35'C. Cytotoxic
(lamage catised by anti-OFA-1 was
assessed by release of 5lCr (sodium
chromate) from labelled target cells. This
assay consisted ofincubating 50 jul of the
washed target-cell suspension, adjusted
to 2 x 105 cells/ml in RPMI 1640 plus 3%
human agamma serum, with equal vol-
times of antisera at the dilutions to be
tested and either rabbit or human com-
plement. This mixture was then incubated
for 1-5 h at, 370C, after which a fraction of
the supernatant was collected and counted
for activity. The % speeifiC 51Cr release951 ONCOFOETAL ANTIGEN----t
NN,as deteriiiined according to the formula:
% speeifiC 5Wr release=
51Cr i-elease with antibody Spontaneous
and complement 5ICr release
Maximum 5lCr release -Spontaneous
(by det,ergent, lysing) 5Wr i-elease
Spoiitaneous release was calculated from
the tubes containing complement alone,
and nevei- exceeded 1401 for anv tai-get
cell. The optimal concentrations of both
complement sources were determined to
be 1:4 by titration with a serum positive
to M14 cells. Highei- concent,rations of
i-abbit complement were toxic to some
target cells. Althotigh this was not, the
case for human complement, at higher
concentrations its ability to participate in
target-cell lysis diminished, possibly be-
ca-Lise ofcomplement inhibitors. The maxi-
inum release for the 4 cell lines ranged
from 80 to 95% by detergent lysing. Cyto-
toxic-antibody titres were taken as the
last serum dilution causing 10% or
greater specific release (I0% endpoint
titre) and always represented a statistic-
TABLEI.-Cytotoxic-antibody titreofmelan-
oma patient'8 8erum aqain8t Ml 4 melan-
onia ce118 in the pre8ence of i-abbit
coniplement*
10% Cytotoxic antibo(ly titi-et-
after absorption by:
allv significant 5ICr release above spon-
taneous release values (P < 0-01). The I0%
endpoint titre was ehosen in view of the
fact that specific lysis did not often exceed
60% in the presence of excess antibodv,
possibly as a reflection of population
heterogeneity. All sera were pre-absorbed
with lymphoblastoid cells atitologous to
each target cell to remove HLA specifi-
cities beforetesting(Pellegrino etal., 1.977).
As shown in Table 1, sera from all 14
melanoma patients contained cytotoxie
antibodv to Ml 4 cells with rabbit comple-
ment, after absorption by lymphoblasts
autologous to the target cells (ML14),
with titrres i-anging from 1:4 to 1:2048.
Positive results were also seen with
human complement, although the reac-
tions wei-e 4-8 titnes less sensitive for end-
point titres. In order to demonstrate the
specificity of the reaction for OFA-1, the
6 sera with the highest titres were tested
byfurtherabsorptiontechniques(Irie etal.,
1976, 1979a). Table I indicates that foetal
brain conipletely abolished antibody acti-
vity from all 6 sera. Foetal liver tissue from
the same foetus did not reduce the anti-
body titre more than two-fold, indicating
that thereactivity to Ml4 was due to anti-
OFA-1 activity as previotisly defined (Irie
et al. , 19761 1979a ,b). Thesefindings are the
first report of cytotoxic antibody gener-
ated in inaii against a foetal antigen
associated with human cancer. Although
other studies have demonstratred cytotoxic
antibodies in cancer patients against
tumour-associated antigens, their cross-
reaction with normal foetal tissue has not
been defined (Bloom, 19,71-62; Bodurtha et
al.5 1975). The detection of humoral
responses to human ttimour-associated
foetal antigens (TAFA) has been limited
to non-functional assays (Irie et al., 1976,
Salinas et al., 1.978) and the eval-Liation of
these antigens as suitable targets foi-
antibody-mediated imm-tine lysis has been
limited to monospecific xenoantisera
(Tompkins et al., 1.976).
The cvtotoxicitx, of these patients' sera
in the presence of htiman complement































































* 1, :4 (illutioii.
t Reciprocal of last, sertim (liltition causing 1000"
or greaterspecific 5lCr i-elease (P < 0-01).
I Lymplioblastoid cells, autologous to Al 14.
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tumour-cell destruction in vivo. However,
while cytotoxic anti-TAFA have been
described in a number of animal tumour
systems, their ability to participate in in
vivo immune protection has varied (Parker
& Rosenberg, 1977; Baldwin et al., 1974).
Furthermore, animal studies indicate that
some TAFA are easily modulated from
the surface of tumour cells by specific
antibody (Ortaldo et al., 1974) which
could explain the lack of anti-TAFA-
mediated protection in some cases. In this
regard, antibody-induced antigenic modu-
lation has been used to explain why cer-
tain viral diseases such as herpes and
SSPE persist in the presence of cytotoxic
anti-viral antibodies (Joseph & Oldstone,
1975).
For these reasons, an anti-OFA-1 serum
(#I) was investigated for its ability to
modulate surface OFA-1expression. Whei-i
Ml4 cells werepre-incubatedwith an excess
amount of this antibody for 30 min or
more at 37'C before adding complement,
cytolysis decreased from 58% to -20%.
This phenomenon was also seen against
the other melanoma (MIO), the sarcoma
(SI) and the breast (436) cell lines (Table
11). Two cell lines, MIO and 436, became
totally resistant to anti-OFA-1 cytolysis
after only I h incubation with antibody.
This result was obtained whether or not
the target cells were washed before adding
complement, eliminating the possibility of
anticomplementary activity in the super-
natant as the cause of the reduced lysis.
TABLEII.-Reduction of OFA-1-mediated
CYtOly8i8 after pre-incubation of tumour








-1 line Oli 'II III
INI14 58 22 17
A110 49 6 0
81 52 N.T.1 32
436 13 N.T. 0
Rabbit compleii-ient clilute(I 1:4.
1:8 dilution.
N'ot tested.
Furthermore, no increase in cytolysis was
seen when additional antibody was added
along with complement after the pre-
incubation period. Additional evidence
from the use of indirect immunofluores-
cence techniques indicates a decrease in
OFA-I+ M14 cells from nearly 90% when
incubated in anti-OFA-1 sera for I h at
4T to only 20% when the incubation
occurs at 37T. Thesefindings suggest that
OFA-1 expression is rapidly modulated
from the surface of tumour cells by
specific antibody, and might explain why
some cancer patients have recurrence of
their disease despite the presence of high
levels of cytotoxic anti-OFA-1. Whether
or not antigenic modulation actually
serves as an escape mechanism may be, in
part, dependent upon the relationship
between the effects of antibody levels on
OFA-1 expression in vivo and the amo-Lint
of bound antibody required for cell lysis.
Experiments are now in progress with
nude mice as an in vivo model to clarify
these points.
These investigations were suppoi-ted by Grants
CA12582 and CA09120 awarded by the National
Cancer Institute (DHEW) and by the Aledical
Researeli Service of the Veterans Administration.
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